However, successful interventions in other CD44-driven malignancies—including head and neck squamous cell carcinoma, breast cancer, osteosarcoma, and leukemia [37]—provide a compelling rationale for investigating similar approaches in TC. The gene discussed is CD44; the disease is osteosarcoma.